Assay development demonstrates dual-recognition autocatalytic amplification for PD-L1 positive extracellular vesicles, highlighting potential applications for tumor immunotherapy.
The PD-L1 protein on extracellular vesicles (EVs) is a promising biomarker for tumor immunotherapy. However, PD-L1
No takes yet. Share an insight, caveat, or question.
Ren et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: